We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Crism Therapeutics Corp | AQSE:AMC.GB | Aquis Stock Exchange | Ordinary Share | VGG042401262 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.50 | 3.00 | 10.00 | 6.50 | 6.50 | 6.50 | 0.00 | 06:56:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jun 2023 to Jun 2024
TIDMAMC
RNS Number : 3732J
Amur Minerals Corporation
15 August 2023
15 August 2023
Amur Minerals Corporation
("Amur" or the "Company")
Cash shell update
Further to the announcement of 6 March 2023 and the disposal of the Company's AO Kun-Manie subsidiary, following which Amur became an AIM Rule 15 cash shell, the board of Amur notes that the Company is required to make an acquisition or acquisitions which constitute(s) a reverse takeover under AIM Rule 14 on or before the date falling six months from the completion of the AO Kun-Manie disposal.
Accordingly, if no such transaction is completed, the Company will be suspended from trading on AIM at 7.30 a.m. on 7 September 2023. Once suspended, Amur will have a further six months to complete a reverse takeover or else admission of the Company's shares on AIM will be cancelled on 8 March 2024.
The board of Amur continues to review a number of reverse takeover opportunities. Further announcements will be made as appropriate.
Enquiries:
Hot Features
Premium
Company Nomad and Broker Public Relations
Amur Minerals Corp. S.P. Angel Corporate BlytheRay
Finance LLP
Robin Young CEO Richard Morrison Megan Ray
Adam Cowl Tim Blythe
+44 (0) 20 3470
+44 (0) 7981 126 818 0470 +44 (0) 20 7138 3203
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCVELBFXVLLBBV
(END) Dow Jones Newswires
August 15, 2023 04:30 ET (08:30 GMT)
1 Year Crism Therapeutics Chart |
1 Month Crism Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
